Business
Bioasis Announces Key Strategic Appointment to its Senior Leadership Team with Addition of Caroline Hill, Ph.D., Leading Research & Development Operations
Bioasis Announces Key Strategic Appointment to its Senior Leadership Team with Addition of Caroline Hill, Ph.D., Leading Research & Development Operations.
About this update from Bioasis Technologies Inc.
[{"type":"text","content":"\n \n BIOASIS \n TECHNOLOGIES INC. (OTCQB:BIOAF; TSX.V:BTI), a biopharmaceutical \n company with a proprietary blood-brain barrier platform delivery \n technology focused on development of therapeutics for the treatment of \n brain cancers and neurodegenerative diseases, today announced a key \n strategic appointment to its senior leadership team with the addition of \n Caroline Hill, Ph.D., as senior vice president, head of research and \n development operations.\n \n \n Dr. Hill brings extensive experience in pharmaceutical product and \n process development, clinical supply manufacturing and corporate \n biotechnology strategy. Dr. Hill will report to Mark Day, Ph.D., \n president and chief executive officer, Bioasis.\n \n \n “The addition of Caroline further illustrates our ability to attract top \n talent to the Bioasis team. Caroline has had an immediate impact on the \n advancement of our xB3-001, xB3-002 and xB3-007 \n programs,” said Dr. Day. “Having worked with Caroline at Bristol Myers \n Squibb in business development and project management, her appointment \n gives me great confidence in our ability to execute on our clinical \n strategy and to meet the significant milestones we have set for \n ourselves for the coming months. I am tremendously delighted to welcome \n Caroline to the Bioasis team. I look forward to her contributions and to \n working with her to drive the Bioasis clinical development efforts \n forward.”\n \n \n Dr. Hill will be responsible for overall operational leadership to \n ensure robust execution of the Bioasis internal pipeline. Dr. Hill will \n have oversight of integrated development planning including timelines, \n vendor management, consultant oversight and pipeline updates to the \n Bioasis board of directors.\n \n \n “Caroline is a dynamic leader, and a fabulous addition to our leadership \n team. I view her laser focus on execution as a major strategic \n advantage,” said Dr. Day.\n \n \n In connection with her appointment, Dr. Hill was awarded 370,000 options \n to purchase Bioasis common shares at a price of $0.68 per share pursuant \n to the terms of Bioasis’ stock option plan. The options have a five-year \n term and vest in equal quarterly instalments over three years.\n \n \n About Caroline Hill, Ph.D.\n \n \n Caroline Hill, Ph.D.,...